Neonatal Respiratory Distress Syndrome (NRDS)

Written by: Khalil Abualhumos, M.D.

Keywords: Surfactant deficiency, preterm infants, respiratory distress, hyaline membrane disease, CPAP, mechanical ventilation, surfactant replacement therapy.

Overview

Neonatal Respiratory Distress Syndrome (NRDS), commonly known as hyaline membrane disease, is a prevalent respiratory condition primarily affecting premature infants due to surfactant deficiency. This deficiency leads to alveolar collapse, reduced lung compliance, and impaired gas exchange, manifesting as tachypnea, grunting, and cyanosis. Diagnosis is typically confirmed through clinical assessment and chest X-ray findings. Early intervention is crucial and may include oxygen therapy, continuous positive airway pressure (CPAP), and surfactant replacement therapy, with the goal of improving respiratory function and preventing complications such as bronchopulmonary dysplasia. Overall, timely recognition and management are essential for improving outcomes in affected neonates.

Buzzwords Scenario: A premature infant born at 28 weeks of gestation presents within hours of birth with rapid breathing (tachypnea), nasal flaring, and grunting during expiration. The baby exhibits a bluish tint around the lips (cyanosis) and has difficulty maintaining adequate oxygen saturation levels. A chest X-ray reveals bilateral ground-glass opacities and air bronchograms, indicating a significant respiratory issue.

Definition

Neonatal Respiratory Distress Syndrome (NRDS) also known as hyaline membrane disease, is a respiratory condition in neonates, primarily affecting preterm infants, due to insufficient surfactant production, leading to alveolar collapse and respiratory distress.

Epidemiology

●       Incidence: Primarily affects premature infants

-   60-80% in infants <28 weeks’ GA.

-   15-30% in infants between 32 and 36 weeks’ GA.

Etiology

Primary cause: Surfactant deficiency (decreased production and secretion).

Risk factors: 

●       Maternal diabetes 

●       Asphyxia 

●       Cesarean delivery

●       Precipitous delivery 

●       Multiple births 

●       Maternal history of previously affected infants.

Risk reducing factors: 

●       Antenatal corticosteroid prophylaxis.

●       Chronic or pregnancy-associated hypertension 

●       Prolonged rupture of membranes

●       Maternal opiate use

Pathophysiology

Prematurity → surfactant does not yet reach lung surfaces → increased alveolar surface tension → alveolar collapse (atelectasis) → stiff lungs → reduced compliance → poor gas exchange → hypoxia and respiratory acidosis (due to hypercapnia) → pulmonary arterial vasoconstriction → increased right-to-left shunting through the foramen ovale and ductus arteriosus plus increased work of breathing → respiratory distress

Atelectasis (atelectrauma), volutrauma, ischemic injury, and oxygen toxicity → progressive lung injury → effusion of proteinaceous material and cellular debris into alveolar spaces → hyaline membranes formation

Clinical Features

Onset: Typically, within minutes of birth (may take hours in large infants)

Initial signs: 

●       Tachypnea 

●       Cyanosis

●       Expiratory grunting 

●       Retractions

●       Nasal flaring

Breath sounds: May be normal or diminished, and fine crackles may be heard upon deep inspiration.

Progression:

●       Untreated RDS typically leads to worsening cyanosis and dyspnea (difficulty breathing).

●       Blood pressure may fall if untreated.

●       Increased cyanosis and pallor

Natural course:

●       Signs typically peak within 3 days.

●       Gradual improvement follows, often indicated by:

-   Spontaneous diuresis (increased urination).

-   Improved blood gas values.

ALERT: Grunting may decrease or disappear as the condition worsens.

ALERT: Apnea and irregular respirations are concerning signs requiring immediate intervention.

Diagnosis

Clinical course of the progression of symptoms helps in diagnosis.

Table 1: Diagnostic tests in neonatal respiratory distress syndrome

NOTE: Initial X-ray may appear normal; the typical pattern develops within the first day.

Special evaluations:

●       In atypical cases of RDS, performing a lung profile (lecithin ratio and phosphatidylglycerol determination) on a tracheal aspirate can aid in diagnosing surfactant deficiency.

Figure 1. Chest X-ray of an infant born at 29 weeks gestation showing reduced lung volume, fine granular opacities, and air bronchograms indicating neonatal respiratory distress syndrome.

Häggström, M. (2018, August 16). Chest radiograph showing signs of infant respiratory distress syndrome (IRDS) [Radiograph]. Own work. https://commons.wikimedia.org/wiki/File:X-ray_of_infant_respiratory_distress_syndrome_(IRDS).png

Management

Initial approach with supportive care; thermoregulation, fluids, respiration, and electrolyte management.

Treatments

●       nCPAP:

-   Nasal continuous positive airway pressure

-   Administration of warm and humidified oxygen

-   Maintain oxygen saturation (Sao2) between 91-95%.

●       Surfactant replacement therapy:

-   Administer intratracheal surfactant to infants who fail nCPAP and require intubation.

-   Improves oxygenation, reduces ventilation needs, and enhances lung compliance.

●       Mechanical ventilation:

-   For infants with severe respiratory failure or persistent apnea.

-   Adjust to avoid lung injury

●       Other pharmacologic therapies include systemic corticosteroids (mainly dexamethasone) which improve respiratory function but may increase risks for long-term complications.

ALERT: Insure permissive hypercapnia (>60 mmhg) to reduce ventilator-associated lung injury, and avoid hyperoxia (keep between 91-95%) to prevent hyperoxia-related lung injury.

ALERT: Empirical antibiotics (e.g., penicillin/ampicillin plus aminoglycoside) should be given until blood culture results are available, to rule out infections like group B streptococcus.

Prevention

Avoid early deliveries: Before 39 weeks' gestation.

Manage high-risk pregnancies: Implement appropriate management strategies, including the administration of antenatal corticosteroids.

Transfer for neonatal care: If premature delivery is unavoidable, transfer to a facility with neonatal care capabilities.

Complications

●       Risk of progressing to respiratory failure and multisystem organ dysfunction

●       Severe impairment of gas exchange

●       Pulmonary air leaks (e.g., pulmonary interstitial emphysema, pneumothorax).

●       Pulmonary hemorrhage

●       Intraventricular hemorrhage (IVH)

●       Bronchopulmonary dysplasia

Prognosis

Mortality rates:

●       Antenatal corticosteroids, postnatal surfactant therapy, and improved ventilation techniques has reduced RDS mortality to approximately 10%.

●       Mortality rates rise as gestational age (GA) decreases.

References

Sprecher, A. J., Acharya, K. K., & Cohen, S. S. (2022). Respiratory Distress Syndrome (Hyaline Membrane Disease). In R. M. Kliegman, J. W. St. Geme III, & N. F. Schor (Eds.), Nelson Textbook of Pediatrics (22nd ed., pp. 1077-1082). Elsevier.